DALLAS, March 04, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Puration, Inc. (PURA) today announced a presentation scheduled for Thursday this week, March 7th, 2019, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival. “We got our tires kicked at the Arnold by some very large distributors that would substantially change our trajectory,†said Brian Shibley, CEO of PURA. EVERx CBD Sports Water debuted it’s all new formula and packaging at the world-renowned Arnold Sports Festival this week in Columbus, Ohio, where EVERx launched for the first time ever in 2017.
Analyst Speculative Buy Recommendation
and $0.25 PPS Target with $0.35 Upside
Goldman Small Cap Research issued a research update
on Puration, Inc. (PURA) last
week recommending a 'speculative-buy' rating
with a target price-per-share of $0.25, with noted potential
upside to the $0.35 mark.
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
[email protected]
(800) 861-1350
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/48fcc68b-84cb-4a6b-b80d-cc655e12d0b8